A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib

Criteria

Inclusion Criteria:

• females, 18 or older

• recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer

• paraffin-embedded tissue block must be available

• measurable disease

• prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting)

• 0, 1 or 2 chemotherapies in the metastatic setting

• adequate organ function

Exclusion Criteria:

• Metastatic disease confined to bone only

• Symptomatic CNS metastasis

• Concurrent medical condition which may increase the risk of toxicity

• Unable to take oral medication